Bloomage Biotechnology Corp. (.SS)_ First take_ 3Q24 NI miss on weaker sales of both skincare and medical device
36氪研究院·2024-11-03 17:16
31 October 2024 | 12:48AM HKT 2131d4eaf4cb4d50b1d51c8af07b64b4 Bloomage Biotechnology Corp. (688363.SS): First take: 3Q24 NI miss on weaker sales of both skincare and medical device Bloomage reported 3Q24 net profit decline of 77% yoy, missing GSe and VA consensus by 80%/84%, mainly driven by weaker sales of both functional skincare and medical device business (incl. medical aesthetics) and higher expenses on admin for restructuring and R&D, partially offset by sell expenses savings. Cathy Chen, CFA +852-29 ...